Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 1
1999 1
2000 1
2004 1
2005 3
2007 3
2008 2
2009 1
2010 4
2011 3
2012 3
2013 9
2014 8
2015 10
2016 5
2017 11
2018 11
2019 10
2020 8
2021 6
2022 13
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 36697102

106 results

Results by year

Filters applied: . Clear all
Page 1
New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study.
Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, Takaguchi K, Atsukawa M, Fukunishi S, Itobayashi E, Tsuji K, Tajiri K, Ochi H, Ishikawa T, Yasuda S, Ogawa C, Toyoda H, Hatanaka T, Nishimura T, Kakizaki S, Kawata K, Shimada N, Tada F, Nouso K, Tsutsui A, Ohama H, Morishita A, Nagano T, Itokawa N, Okubo T, Arai T, Kosaka H, Imai M, Naganuma A, Nakamura S, Koizumi Y, Kaibori M, Iijima H, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Cancer Med. 2023 Mar;12(6):6980-6993. doi: 10.1002/cam4.5495. Epub 2022 Dec 9. Cancer Med. 2023. PMID: 36484470 Free PMC article.
Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Aoki T, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 Clinics in Japan (HCC 48) Group. Tada T, et al. Eur J Gastroenterol Hepatol. 2022 Aug 1;34(8):857-864. doi: 10.1097/MEG.0000000000002398. Epub 2022 Jun 29. Eur J Gastroenterol Hepatol. 2022. PMID: 35802527
Liver resection for single large hepatocellular carcinoma: a prognostic factors study.
Nguyen-Khac V, Brustia R, Rhaiem R, Regnault H, Sessa A, Mule S, Duvoux C, Laurent A, Leroy V, Calderaro J, Luciani A, Roudot-Thoraval F, Amaddeo G, Sommacale D. Nguyen-Khac V, et al. Ann Hepatol. 2022 Nov-Dec;27(6):100739. doi: 10.1016/j.aohep.2022.100739. Epub 2022 Jul 1. Ann Hepatol. 2022. PMID: 35781089 Free article.
106 results